Pivaris BioScience GmbH is a privately held Research
R&D:A novel, broad-acting antiviral peptide targeting double-stranded DNA viruses such as herpes simplex virus, cytomegalovirus, vaccinia virus, polyomavirus and adenoviruses has been identified. This first-in-class inhibitor is under evaluation for its use in the treatment of infections caused by double-stranded DNA viruses. The proprietary lead candidate of Pivaris BioScience GmbH is also being evaluated on various other virus models, including RNA viruses such as SARS-CoV-2.
Services:Pivaris BioScience GmbH offers consultancy for scientific projects in the area of biotechnology and can assist in solving technical and scientific problems. Pivaris BioScience GmbH also offers molecular and cell biology services - together with our partners, a wide range of applications can be covered, including cloning, PCR, cell-based assays, and biochemical assays.